

Impact of Opportunistic *Mycobacterium tuberculosis* Infection on the Phenotype of Peripheral Blood T Cells of AIDS Patients

Germán Bernal-Fernández,¹ Carlos Hermida,⁴ Patricia Espinosa-Cueto,¹
Ana Cristina Cubilla-Tejeda,² Jesús Fidel Salazar-González,³ Librado Ortiz-Ortiz,¹
Rosario Leyva-Meza,¹ Hugo Diaz-Silvestre,¹ and Raul Mancilla^{1*}

¹Departamento de Inmunología, Instituto de Investigaciones Biomédicas,
Universidad Nacional Autónoma de México, Mexico City, Mexico

²Laboratorio de Inmunología Celular y Molecular, Facultad de Ciencias Químicas,
Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico

³Divisions of Hematology and Oncology, Department of Medicine,
University of Alabama–Birmingham, Birmingham, Alabama

⁴Hospital de Enfermedades Infecciosas, Centro Médico La Raza,
Instituto Mexicano del Seguro Social, Mexico City, Mexico

While the detrimental consequences of opportunistic tuberculosis (TB) in the course and outcome of HIV-1 infection are well studied, little information about the impact of the mycobacterial infection on the phenotype of T lymphocytes is available. In this study we analyzed by cytofluorimetry the peripheral blood T cell phenotype of 13 patients with AIDS, 23 HIV-1 negative patients with active pulmonary TB, nine HIV-1/*Mycobacterium tuberculosis* coinfecting individuals, and 21 age- and sex-matched healthy controls. CD4⁺ T cells were equally depleted in AIDS and coinfection ($P < 0.001$). The findings suggest a rescuing effect of the added mycobacterial

infection. CD3 T cell loss was not observed in coinfection, whereas it was severe in AIDS ($P < 0.001$). Similar (albeit less striking) effects were observed with other markers (CD45RA, CD45RO, and CD27) that were diminished in CD4⁺ T cells of AIDS patients. Apparent detrimental effects of the added mycobacterial infection were the increased expression of the proapoptotic molecule CD95 on CD4⁺ T cells, and decreased expression of the major costimulatory molecule CD28 on CD8⁺ T cells. In this work we show that *M. tuberculosis* infection modifies the T cell phenotype of the HIV-1 infected individual. *J. Clin. Lab. Anal.* 20:80–86, 2006. © 2006 Wiley-Liss, Inc.

Key words: HIV-1; AIDS; tuberculosis; flow cytometry; T cells

INTRODUCTION

The synergistic interaction of *Mycobacterium tuberculosis* (Mtb) and human immunodeficiency virus type 1 (HIV-1) poses an important challenge to public health, particularly in less-developed countries. The impact of the HIV epidemic on the incidence of tuberculosis (TB) is important: 9% of the 8.3 million new TB cases and 12% of the 1.8 million TB deaths in 2000 were HIV-related (1). On the other hand, TB aggravates the course of HIV-1 infection and is the cause of 11% of all adult acquired immunodeficiency syndrome (AIDS) deaths (1). The superimposed Mtb infection, by further activating the immune system, favors cell infection and intracellular viral replication (2).

The high susceptibility of patients with AIDS to Mtb infection is probably related to a progressive decline of CD4⁺ T cells (3), which play a central role in the immune response to Mtb (4). Moreover, CD4⁺ T cells are dysfunctional even before depletion occurs, with

Grant sponsor: Consejo Nacional de la Investigación Científica y Tecnológica; Grant number: 41588-8

*Correspondence to: Raul Mancilla, M.D., Departamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Apartado Postal 70228, Ciudad Universitaria, Mexico City 04510, Mexico.

E-mail: mancilla@correo.biomedicas.unam.mx

Received 16 September 2005; Accepted 16 September 2005

DOI 10.1002/jcla.20105

Published online in Wiley InterScience (www.interscience.wiley.com).

poor in vitro blastogenic responses (5–7), diminished cytotoxic activity (8), increased apoptosis (9,10), and defective T cell costimulation, which is associated with decreased expression of CD28 and CD40L on CD4+ T cells (11–13). High levels of soluble CD27 and CD30 in serum that correlate with high viral loads in plasma and CD4+ T cell loss have also been reported (14,15). Related to the above T cell defects, particularly CD4+ T cell depletion, HIV-1 infection is frequently complicated by opportunistic infections, including TB (3). AIDS/TB coinfecting patients present higher viral loads and follow a poor clinical course that is related to several factors (16). Lymphocyte activation is crucial for viral infection and replication (17,18), and mycobacteria are potent activators of CD4+ T cells (4). In addition, the T cells of TB patients produce high levels of tumor necrosis factor alpha and interleukin 6, which promote viral replication (2,19). On the other hand, a defective T cell response is frequently observed in TB, which is manifested by CD4+ T cell lymphopenia and anergy (20,21). In addition, as observed in AIDS, abnormal apoptosis of T cells and dysregulation of the cytokine network with predominance of a Th2 response are frequently observed in TB patients (22,23).

In view of the above data, we considered it possible that in dually infected patients the impact of mycobacterial antigens on the immune system of HIV-1-infected individuals might modify the phenotype of peripheral blood T cells. To test this hypothesis, we investigated the phenotype of peripheral blood T cells in patients with AIDS, patients with pulmonary TB, and AIDS/TB-coinfecting individuals, with an emphasis on the expression of T cell costimulatory molecules.

MATERIALS AND METHODS

Study Population

This study included 13 AIDS patients, 23 HIV-1-negative patients with active pulmonary TB, and nine AIDS/TB-coinfecting individuals. Patients were recruited at the Centro Estatal de Información sobre SIDA in San Luis Potosí, México, and the Hospital de Infectología, Centro Médico La Raza, Instituto Mexicano del Seguro Social, in Mexico City. The HIV-1 diagnosis was done by a standard screening enzyme-linked immunosorbent assay (ELISA; UmElisa HIV 1+2 Reconvinant, La Havana, Cuba) and confirmed by immunoblotting (Grupo Roche Syntex, Mexico City, Mexico). At the time of bleeding, patients were taking medications such as zidovudine (AZT), didanosine (ddI), and zalcitabine (ddC). The TB diagnosis was based on clinical and chest X-ray data and confirmed by sputum culture and/or by demonstrating acid-fast bacilli on sputum smears. For controls, blood samples were obtained from 21 individuals

who were HIV-1-negative and clinically healthy. The AIDS patients (two females and 11 males) varied in age from 28 to 51 years (mean = 34 ± 6 years). The AIDS/TB-coinfecting patients (two females and seven males) varied in age from 22 to 56 years (mean = 35 ± 13 years). The TB patients (10 females and 13 males) ranged in age from 29 to 78 years. The average age was 55 ± 14 years, and six patients (26%) were elderly (≥ 65 years old). Of the 23 TB patients, 10 who matched the age of the AIDS and coinfecting groups were chosen for comparative statistical analysis. These 10 HIV-1-negative TB patients (five females and five males) varied in age from 29 to 49 years (mean = 41 ± 7 years). The healthy controls (11 females and 10 males) varied in age from 21 to 64 years (mean = 34 ± 15 years).

Monoclonal Antibodies

Monoclonal antibodies (mAb), unlabeled or labeled with fluorescein isothiocyanate, R-phycoerythrin, or R-phycoerythrin-Cy5, were obtained from various laboratories. mAb to CD3 (clone UCHT1, IgG1), CD45RA (clone F8-11-13, IgG1), CD30L (clone MB1, IgG2b), CD40L (clone TRAP1.3.6, IgG1), and CD27 (clone LT27, IgG2a) were purchased from Serotec (Raleigh, NC). mAb to CD4 (clone RPA-T4, IgG1), CD28 (clone CD28.2, IgG1), CD95 (clone DX2, IgG1), and CD45RO (clone UCHL1, IgG2b) were obtained from Pharmingen (San Diego, CA). mAb against CD4 (clone MT310, IgG1), CD8 (clone DK25, IgG1), and CD30 (clone Ber-H2, IgG1) were purchased from the Dako Corporation (Carpinteria, CA). Appropriate isotype control antibodies were employed.

Flow Cytometry Assay

Blood samples were obtained from patients and controls by venipuncture in Vacutainer tubes (Becton Dickinson, San Jose, CA) with EDTA as anticoagulant. Peripheral blood mononuclear cells (PBMC) were isolated by centrifugation in Histopaque-1077 gradient (Sigma, St. Louis, MO). PBMC (5×10^5) were stained with mAbs or isotype controls for 30 min in the dark at 4°C, and washed in PBS with 1% fetal bovine serum and 0.1% sodium azide. The cells were then incubated with the indicated labeled secondary antibodies for 30 min. After the cells were rinsed they were fixed with 1% paraformaldehyde in PBS. At least 10,000 cells were analyzed in a two-color FACScanTM (Becton Dickinson, San Jose, CA) operating with Cellquest software and a 488-nm argon laser. The cells were gated according to typical forward and right angles to establish a lymphocyte gate that excluded blasts, cell debris, and cell aggregates.

Statistical Analysis

To establish statistical differences between groups, we analyzed the data with a one-way analysis of variance (ANOVA) and Tukey post test using GraphPad Prism version 3.02 for Windows (GraphPad Software, San Diego, CA).

RESULTS

The statistically significant changes observed in 23 TB patients were as follows: decreased CD3+ T cell counts ($P<0.05$), severe depletion of CD4+ T lymphocytes ($P<0.001$), and low CD8+ T cell counts ($P<0.01$). CD4+/CD45RO+ and CD4/CD30 T cell subsets were increased in percentage ($P<0.01$ and $P<0.05$, respectively). The expression of the CD28 T cell costimulatory molecule on CD4+ and CD8+ T cells was severely diminished ($P<0.001$).

In the AIDS patients, flow cytometry results revealed a severe CD3 T cell loss (controls: $1,518 \pm 19/\text{mm}^3$; AIDS: $720 \pm 417/\text{mm}^3$) that was highly significant ($P<0.001$). CD3 T cell counts in AIDS/TB-coinfection ($911 \pm 582/\text{mm}^3$) and TB patients ($1209 \pm 676/\text{mm}^3$) were not significantly different from those of controls.

Table 1 and Figs. 1 and 2 show the results of the flow cytometry analysis of CD4+ T cells. As expected, in AIDS patients CD4+ T cells were severely diminished in both percentage and absolute numbers ($P<0.001$). In AIDS/TB coinfection the loss of CD4+ T cells was also very severe (percentage and absolute numbers, $P<0.001$). HIV-1-negative pulmonary TB also exhibited CD4+ T cell loss, but of lesser significance (percentage and absolute number, $P<0.01$). Regarding the expression of the CD45RA naïve T cell marker, the CD4+/CD45RA+ T cell subset was severely diminished in

AIDS ($P<0.001$), while in coinfection the loss of this subset was less significant ($P<0.01$). Markedly reduced CD4+/CD45RO+ T cell counts were observed in AIDS patients ($P<0.001$), whereas these cells did not differ significantly between coinfecting individuals and controls. As regards the proapoptotic CD95 molecule, in AIDS the absolute number of CD4+ T cells that expressed this marker was decreased ($P<0.01$) and the percentage was unchanged. In AIDS/TB-coinfection the absolute number of CD4+/CD95+ T cells was also diminished ($P<0.05$), but the percentage was higher than that of controls ($P<0.05$). We also analyzed the expression of the T cell costimulatory molecules CD27, CD30, CD30L, and CD40L, which belong to the TNF family (24), and of CD28, a member of the immunoglobulin superfamily (25). In AIDS patients the CD4/CD27 T cell subset was diminished in absolute numbers ($P<0.05$), whereas in AIDS/TB-coinfected individuals these cells were within the normal range. In HIV-1-negative TB patients CD27 expression was not altered. Contrary to findings in the literature (15), in this study the expression of CD30 and CD30L on T cells of AIDS patients was no different from that of controls. These cells were also within the normal range in coinfecting and TB patients. In all study groups the expression of CD40L on CD4+ T cells was within control values. As regards the major T cell costimulatory molecule CD28, its expression in CD4+ T cells of AIDS patients was severely decreased in absolute numbers ($P<0.001$). In HIV-1-negative TB patients the CD4+/CD28+ T cell subset was also diminished ($P<0.05$). In AIDS/TB coinfection, the diminished expression of CD28 on CD4+ T cells was similar to that observed in AIDS ($P<0.001$).

Table 2 shows the results of the flow cytometry analysis of CD8+ T cells. In all study groups the

TABLE 1. The peripheral blood CD4+ T cell phenotype in HIV-1/*Mycobacterium tuberculosis* coinfecting patients*

| Marker | Controls (n = 21) | | AIDS (n = 13) | | HIV/TB (n = 9) | | TB (n = 10) | |
|------------|-------------------|-----------|--------------------|------------------------|----------------------|------------------------|---------------------|------------------------|
| | % | # | % | # | % | # | % | # |
| CD3/CD4 | 37 ± 11 | 884 ± 392 | 8 ± 6 ^c | 118 ± 117 ^c | 10 ± 10 ^c | 176 ± 215 ^c | 24 ± 8 ^b | 488 ± 195 ^b |
| CD4/CD45RA | 25 ± 13 | 237 ± 146 | 27 ± 35 | 34 ± 64 ^c | 39 ± 28 | 224 ± 229 ^b | 35 ± 24 | 181 ± 143 |
| CD4/CD45RO | 59 ± 19 | 463 ± 145 | 59 ± 25 | 70 ± 67 ^c | 66 ± 20 | 139 ± 167 | 66 ± 18 | 311 ± 167 |
| CD4/CD95 | 37 ± 26 | 410 ± 349 | 58 ± 25 | 59 ± 57 ^b | 72 ± 38 ^a | 99 ± 133 ^a | 59 ± 39 | 316 ± 267 |
| CD4/CD27 | 37 ± 36 | 400 ± 449 | 26 ± 29 | 23 ± 28 ^a | 38 ± 30 | 66 ± 102 | 57 ± 43 | 293 ± 240 |
| CD4/CD30 | 1 ± 2 | 9 ± 12 | 3 ± 8 | 2 ± 6 | 0 ± 0 | 0 ± 0 | 4 ± 4 | 20 ± 19 |
| CD4/CD30L | 2 ± 30 | 146 ± 183 | 45 ± 28 | 74 ± 59 | 24 ± 17 | 59 ± 62 | 16 ± 16 | 105 ± 99 |
| CD4/CD40L | 9 ± 21 | 61 ± 107 | 33 ± 38 | 31 ± 39 | 22 ± 18 | 29 ± 33 | 2 ± 4 | 7 ± 10 |
| CD4/CD28 | 69 ± 30 | 676 ± 378 | 16 ± 29 | 47 ± 49 ^c | 54 ± 39 | 136 ± 232 ^c | 59 ± 42 | 337 ± 313 ^a |

*Media, absolute cell counts and percentage ± standard deviation of flow cytometry results. Statistically significant differences between groups were determined by one-way ANOVA with Tukey post test.

^aSignificantly different from the control group ($P<0.05$).

^bSignificantly different from the control group ($P<0.01$).

^cSignificantly different from the control group ($P<0.001$).




Fig. 1. Flow cytometry analysis of peripheral blood cells from 13 AIDS patients, nine HIV-1/*M. tuberculosis*-coinfected patients, and 10 HIV-1-negative patients with pulmonary TB. Significant results are shown in absolute numbers and percentage of CD4+, CD4+/CD45RA+, and CD4+/CD95. The box plot represents the median, 25/75 percentile, and extreme values. **a:** Significantly different from control group ($P < 0.05$). **b:** Significantly different from control group ($P < 0.01$). **c:** Significantly different from control group ($P < 0.001$).

percentages and absolute numbers of these cells did not differ from those of controls. However, CD8+ cells showed a tendency to increase (AIDS/TB: $592 \pm 430/\text{mm}^3$; AIDS: $458 \pm 343/\text{mm}^3$). Expression of CD45RA and CD45RO on CD8+ T cells of all study groups was not altered. Expression of CD95 on CD8+ T cells of AIDS, AIDS/TB coinfection, and HIV-1-negative TB groups was also within control values. Regarding the T cell costimulatory molecules, the expression of CD27, CD30, CD30L, and CD40L on CD8+ T cells was within control values in all study groups. In contrast, in AIDS patients the number of CD8+/CD28 T cells was reduced in both absolute numbers and percentage ($P < 0.01$). In

HIV-negative TB patients the absolute numbers of these cells was also reduced ($P < 0.01$). In AIDS/TB coinfection, CD28 expression on CD8+ T cells was severely diminished in percentage but not in absolute numbers ($P < 0.001$). Figures 1 and 2 show a graphic representation of the statistically significant results.

DISCUSSION

The consequences of opportunistic TB on the clinical course and outcome of HIV-1 infection have been well studied (1). In contrast, information regarding the impact of the mycobacterial infection on the T cell




Fig. 2. Flow cytometry analysis of peripheral blood cells from 13 AIDS patients, nine HIV-1/*M. tuberculosis*-coinfected patients, and 10 HIV-1-negative patients with pulmonary TB. Significant results are shown in absolute numbers and percentage of CD4⁺/CD28⁺, and CD8⁺/CD28⁺ T cells. The box plot represents the median, 25/75 percentile, and extreme values. **a:** Significantly different from control group ($P < 0.05$). **b:** Significantly different from control group ($P < 0.01$). **c:** Significantly different from control group ($P < 0.001$).

TABLE 2. The peripheral blood CD8⁺ T cell phenotype in HIV-1/*Mycobacterium tuberculosis* coinfecting patients*

| Marker | Controls (n = 21) | | AIDS (n = 13) | | HIV/TB (n = 9) | | TB (n = 10) | |
|------------|-------------------|-----------|----------------------|----------------------|----------------------|-----------|-------------|----------------------|
| | % | # | % | # | % | # | % | # |
| CD3/CD8 | 20 ± 8 | 473 ± 216 | 31 ± 24 | 4558 ± 343 | 37 ± 19 | 592 ± 430 | 13 ± 8 | 244 ± 142 |
| CD8/CD45RA | 55 ± 27 | 302 ± 182 | 42 ± 39 | 194 ± 247 | 27 ± 17 | 183 ± 153 | 48 ± 21 | 192 ± 170 |
| CD8/CD45RO | 47 ± 26 | 273 ± 174 | 39 ± 28 | 267 ± 216 | 36 ± 12 | 224 ± 229 | 60 ± 27 | 168 ± 137 |
| CD8/CD95 | 42 ± 26 | 251 ± 181 | 36 ± 36 | 190 ± 245 | 48 ± 39 | 443 ± 436 | 45 ± 36 | 169 ± 183 |
| CD8/CD27 | 32 ± 31 | 146 ± 138 | 25 ± 29 | 66 ± 67 | 13 ± 13 | 104 ± 128 | 33 ± 33 | 92 ± 100 |
| CD8/CD30 | 6 ± 22 | 16 ± 55 | 1 ± 2 | 7 ± 14 | 0 ± 0 | 0 ± 0 | 7 ± 8 | 17 ± 23 |
| CD8/CD30L | 26 ± 39 | 110 ± 160 | 27 ± 45 | 19 ± 26 | 4 ± 5 | 27 ± 38 | 13 ± 8 | 32 ± 21 |
| CD8/CD40L | 10 ± 25 | 38 ± 64 | 22 ± 37 | 58 ± 156 | 2 ± 3 | 18 ± 34 | 7 ± 9 | 14 ± 14 |
| CD8/CD28 | 53 ± 21 | 302 ± 110 | 16 ± 29 ^b | 58 ± 90 ^b | 11 ± 16 ^c | 111 ± 201 | 28 ± 26 | 77 ± 79 ^b |

*Media, absolute cell counts and percentage ± standard deviation of flow cytometry results. Statistically significant differences between groups were determined by one-way ANOVA with Tukey post test.

^aSignificantly different from the control group ($P < 0.05$).

^bSignificantly different from the control group ($P < 0.01$).

^cSignificantly different from the control group ($P < 0.001$).

phenotype of the HIV-1-infected individual is scanty. Here we analyzed by flow cytometry the peripheral blood T cells of AIDS patients with and without pulmonary TB. In AIDS patients opportunistic TB did not further decrease CD4⁺ T cell counts. This was somewhat unexpected since two conditions characterized by CD4⁺ T cell loss converge in the coinfecting

individual. In HIV-1 infection, CD4⁺ T cell loss is progressive and severe and predicts a bad outcome (3). In TB, CD4 lymphopenia is less frequent and severe, is not always associated with a bad outcome, and may be corrected with antituberculous chemotherapy (21).

Our observations suggest a rescuing effect of the superimposed mycobacterial infection. The reversal of

the severe CD3+ T cell loss in AIDS patients to healthy control values in coinfecting individuals is noteworthy. This finding could be relevant since CD3+ T cell loss may predict the development of AIDS independently of CD4 counts (26).

CD4+ T cells that express the cell-surface isoforms CD45RA and CD45RO are major targets in HIV-1 infection (27). The CD45RA marker characterizes naïve cells that differentiate into CD45RO memory cells after antigen activation (28). In this work we found that the diminished expression of CD45RA and CD45RO on CD4+ T cells was partially reversed in coinfecting individuals. A similar (albeit less striking) rescuing effect was observed in the diminished expression of CD27 and CD95 on CD4+ T cells. The latter is an interesting finding because HIV-1 infection is known to increase the expression of CD95 on T cells, which is associated with decreasing peripheral blood CD4+ T cell counts (9,10,29).

The interaction of CD28 with its ligand B7 plays a crucial role in T cell activation (25). In HIV-1 infection CD28 plays both positive and negative roles. CD4+ T cell activation through TCR and CD28 promotes viral transcription (30). CD28 costimulation may also inhibit HIV-1 infection by downregulating chemokine receptor expression (31). Decreased expression of CD28 on both CD4+ and CD8+ T cells has been observed in HIV-1 infection (11,32), and depletion of the CD8+/CD28+ T cell subset was reported in a previous study of TB patients (33). In our TB patients we observed a severely decreased expression of CD28 on both CD4+ and CD8+ T cells. We also found a decreased expression of CD28 on CD4+ T cells of AIDS patients that was not modified in the coinfecting patients. The CD8+/CD28+ T cell subset was similarly reduced and, interestingly, depletion of this subset was higher in AIDS/TB coinfection. The effects of CD8+/CD28+ T cell loss in the course of HIV-1 infection are unknown. CD8+ CD28- T cells differ from CD28+ CD8+ T cells in their high catalytic activity, elevated IFN- γ production, and increased tendency to apoptosis (32,34). The diminished expression of CD28 on CD8+ T cells has been attributed to repeated antigenic stimulation (11,32), as observed in AIDS and TB.

In summary, in this study we found that the T cell phenotype of AIDS patients is impacted by additional *M. tuberculosis* infection inducing both negative and positive effects on peripheral blood T cells. A prospective follow-up study is needed to determine whether these changes influence the course and outcome of the AIDS/TB-coinfecting individual. It is possible, however, that the increased expression of the proapoptotic molecule CD95 on CD4+ T cells, and the decreased expression of the major costimulatory molecule CD28

on CD8+ T cells related to the additional mycobacterial infection further compromise T cell function in the HIV-1-infected patient.

REFERENCES

1. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. *Arch Intern Med* 2003;163:1009–1021.
2. Garrait V, Cadranet J, Esvant H, et al. Tuberculosis generates a microenvironment enhancing the productive infection of local lymphocytes by HIV. *J Immunol* 1997;159:2824–2830.
3. Fahey JL, Prince H, Weaver M, et al. Quantitative changes in T helper or T suppressor/cytotoxic lymphocyte subsets that distinguish acquired immune deficiency syndrome from other immune subset disorders. *Am J Med* 1984;76:95–100.
4. Flynn JL, Chan J. Immunology of tuberculosis. *Annu Rev Immunol* 2001;19:93–129.
5. Musey LK, Krieger JN, Hughes JP, Schacker TW, Corey L, McElrath MJ. Early and persistent human immunodeficiency virus type 1 (HIV-1)-specific T helper dysfunction in blood and lymph nodes following acute HIV-1 infection. *J Infect Dis* 1999;180:278–284.
6. Lane HC, Depper JM, Greene WC, Whalen G, Waldmann TA, Fauci AS. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome: evidence for a selective defect in soluble antigen recognition. *N Engl J Med* 1985;313:79–84.
7. Janosy G, Borthwick N, Lomnitzer R, et al. Lymphocyte activation in HIV-1 infection. I. Predominant proliferative defects among CD45RO+ cells of the CD4 and CD8 lineages. *AIDS* 1993;7:613–624.
8. Ogg GS, Kostense S, Klein MR, et al. Longitudinal phenotypic analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes: correlation with disease progression. *J Virol* 1999;73:9153–9160.
9. Böhler T, Baumler C, Herr I, Groll A, Kurz M, Debatin KM. Activation of the CD95 system increases with disease progression in human immunodeficiency virus type 1-infected children and adolescents. *Pediatr Infect Dis J* 1997;16:754–759.
10. Katsikis PD, Wunderlich ES, Smith CA, Herzenberg LA, Herzenberg LA. Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals. *J Exp Med* 1995;181:2029–2036.
11. Borthwick NJ, Bofill M, Gombert WM, et al. Lymphocyte activation in HIV-1 infection. II. Functional defects of CD28 T-cells. *AIDS* 1994;8:431–441.
12. Subauste CS, Wessendarp M, Smulian AG, Frame PT. Role of CD40 ligand signaling in defective type 1 cytokine response in human immunodeficiency virus infection. *J Infect Dis* 2001;183:1722–1731.
13. Vanham G, Penne L, Devalck J, et al. Decreased CD40 ligand induction in CD4 T cells and dysregulated IL-12 production during HIV infection. *Clin Exp Immunol* 1999;117:335–342.
14. De Milito A, Aleman S, Marenzi R, et al. Plasma levels of soluble CD27: a simple marker to monitor immune activation during potent antiretroviral therapy in HIV-1-infected subjects. *Clin Exp Immunol* 2002;127:486–494.
15. Pizzolo G, Vinante F, Morosato L, et al. High serum level of the soluble form of CD30 molecule in the early phase of HIV-1 infection as an independent predictor of progression to AIDS. *AIDS* 1994;8:741–745.

16. Collins KR, Quinones-Mateu ME, Toossi Z, Arts EJ. Impact of tuberculosis on HIV-1 replication, diversity, and disease progression. *AIDS Rev* 2002;4:165–176.
17. Kestens L, Vanham G, Vereecken C, et al. Selective increase of activation antigens HLA-DR and CD38 on CD4+ CD45RO+ T lymphocytes during HIV-1 infection. *Clin Exp Immunol* 1994; 95:436–441.
18. Hertoghe T, Wajja A, Ntambi L, et al. T cell activation, apoptosis and cytokine dysregulation in the (co)pathogenesis of HIV and pulmonary tuberculosis. *Clin Exp Immunol* 2000;122:350–357.
19. Osborn L, Kunkel S, Nabel GJ. Tumor necrosis factor- α and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. *Proc Natl Acad Sci USA* 1989;86:2336–2340.
20. Delgado JC, Tsai EY, Thim S, et al. Antigen-specific and persistent tuberculin anergy in a cohort of pulmonary tuberculosis patients from rural Cambodia. *Proc Natl Acad Sci USA* 2002; 99:7576–7581.
21. Pilheu JA, De Salvo MC, Gonzalez J, Rey D, Elias MC, Rupp MC. CD4+ T-lymphopenia in severe pulmonary tuberculosis without evidence of human immunodeficiency virus infection. *Int J Tuberc Lung Dis* 1997;1:422–426.
22. Hirsch CS, Toossi Z, Johnson JL, et al. Augmentation of apoptosis and interferon-gamma production at sites of active *Mycobacterium tuberculosis* infection in human tuberculosis. *J Infect Dis* 2001;183:779–788.
23. Lienhardt C, Azzurri A, Amedei A, et al. Active tuberculosis in Africa is associated with reduced Th1 and increased Th2 activity *in vivo*. *Eur J Immunol* 2002;32:1605–1613.
24. Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? *Nat Rev Immunol* 2003;3:609–620.
25. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. *Nat Rev Immunol* 2002;2:116–126.
26. Margolick JB, Donnenberg AD, Chu C, O’Gorman MR, Giorgi JV, Munoz A. Decline in total cell count is associated with onset of AIDS, independent of CD4(+) lymphocyte count: implications for AIDS pathogenesis. *Clin Immunol Immunopathol* 1998;88: 253–263.
27. Jaleco AC, Covas MJ, Pinto LA, Victorino RM. Distinct alterations in the distribution of CD45RO+ T-cell subsets in HIV-2 compared with HIV-1 infection. *AIDS* 1994;8:1663–1668.
28. de Jong R, Brouwer M, Miedema F, van Lier RA. Human CD8+ T lymphocytes can be divided into CD45RA+ and CD45RO+ cells with different requirements for activation and differentiation. *J Immunol* 1991;146:2088–2094.
29. Silvestris F, Cafforio P, Frassanito MA, et al. Overexpression of Fas antigen on T cells in advanced HIV-1 infection: differential ligation constantly induces apoptosis. *AIDS* 1996;10:131–141.
30. Barker E, Bossart KN, Levy JA. Differential effects of CD28 costimulation on HIV production by CD4+ cells. *J Immunol* 1998;161:6223–6227.
31. Carroll RG, Riley JL, Levine BL, et al. Differential regulation of HIV-1 fusion cofactor expression by CD28 co-stimulation of CD4+ T cells. *Science* 1997;276:273–276.
32. Choremi-Papadopoulou H, Viglis V, Gargalianos P, Kordossis T, Iniotaki-Theodoraki A, Kosmidis J. Downregulation of CD28 surface antigen on CD4+ and CD8+ T lymphocytes during HIV-1 infection. *J Acquir Immune Defic Syndr* 1994;7:245–253.
33. Ponticciello A, Perna F, Sturkenboom MC, Marchettiello I, Bocchino M, Sanduzzi A. Demographic risk factors and lymphocyte populations in patients with tuberculosis and their healthy contacts. *Int J Tuberc Lung Dis* 2001;5:1148–1155.
34. Vingerhoets JH, Vanham GL, Kestens LL, et al. Increased cytolytic T lymphocyte activity and decreased B7 responsiveness are associated with CD28 down-regulation on CD8+ T cells from HIV-infected subjects. *Clin Exp Immunol* 1995;100:425–433.